Lassen Therapeutics
San Diego
About Lassen Therapeutics
Lassen Therapeutics develops antibodies as potential treatments for fibrosis, rare diseases, and oncology. The company’s lead candidate is LASN01, a monoclonal antibody targeting IL-11 receptor alpha (IL-11R). IL-11, a member of the IL-6 family of cytokines, is a central mediator of fibrosis, and blocking its activity has the potential to be more effective than targeting other factors such as TGF-╬▓ and CTGF. IL-11 is also a pivotal effector of tumor microenvironment organization and tumor growth, playing a key role as a mediator between cancer and stromal cells.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $116.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Dec 2023)
- Website: lassentherapeutics.com
- Phone: +1 (858) 251-7528
Industries & Categories
Biotechnology, Health Care, Life Science, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/lassen-therapeutics-53480 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.